Developed by the PHA Scientific Leadership Council and jointly provided by the Washington University School of Medicine in St. Louis, Continuing Medical Education, PHA Preceptorship Program: A Collaborative Approach for Clinicians on the Front Line offers the latest information on PAH diagnosis and management to physicians and other health professionals.
This interactive CME session will help build links among community PAH specialists and front-line clinicians by creating new avenues for communication and supporting comprehensive, state-of-the-art care for our patients with PAH
- Programs are generally scheduled from 9:00 a.m. – 3:30 p.m.
- A complimentary lunch is provided
- This program is FREE
- 2020 Preceptorships will be announced in late summer 2020.
Preceptorships completed in 2019:
- Nashville, Tenn. Pediatric Preceptorship
- Washington, D.C.
- Aurora, Colorado
- Los Angeles, California
This activity has been designed for pulmonologists, cardiologists, rheumatologists, internists, and primary care physicians, as well as nurses, physician assistants, and other allied health professionals who help care for patients with PAH.
The PHA Preceptorship Program is designed to improve competence, performance, and patient care practices by instructing front-line clinicians in the highest quality of care for patients with PAH by combining didactic discourse and highly interactive case-based discussion. At the conclusion of this program, participants should be able to:
- Define key pathophysiologic and epidemiologic components of PAH
- Accurately diagnose patients through comprehensive screening and early recognition of symptoms
- Evaluate the patient’s condition and prescribe optimal long-term management, including knowing when and how to treat and when to consult with colleagues at an established PAH center
- Tailor comprehensive care for complex patient populations
CONTINUING EDUCATION PROVIDED BY
Washington University School of Medicine in St. Louis, Continuing Medical Education.
In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Washington University School of Medicine in St. Louis designates this live activity for a maximum of 5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
It is the policy of Washington University School of Medicine in St. Louis, Continuing Medical Education, that planners, faculty and other persons who may influence content of this CME activity disclose all relevant financial relationships with commercial interests in order for CME staff to identify and resolve any potential conflicts of interest prior to the educational activity. Faculty must also disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation. Detailed disclosures will be made in activity handout materials.
- Jean M. Elwing, M.D., FCCP, Chair, University of Cincinnati College of Medicine
- Eric D. Austin, M.D., MSCI, Vanderbilt University School of Medicine
- Christopher F. Barnett, M.D., M.P.H., MedStar Washington Hospital Center
- Kelly Chin, M.D., MSCS, University of Texas Southwestern Medical Center
- Lorinda Chung, M.D., M.S., Stanford Health Care
- Richard A. Krasuski, M.D., FACC, FAHA, FESC, Duke University Medical Center
- Gustavo A. Heresi, M.D., M.S., Respiratory Institute Cleveland Clinic
- Tim Lahm, M.D., Indiana University School of Medicinehttps://phassociation.org/wp-admin/post.php?post=2720&action=edit#
- Vallerie V. McLaughlin, M.D., FACC, FAHA, FCCP, Committee Advisor, Michigan Medicine
This activity is jointly provided by Washington University School of Medicine in St. Louis, Continuing Medical Education and the Pulmonary Hypertension Association.
This activity is supported by educational grants from:
Janssen Pharmaceuticals, Inc.
United Therapeutics Corporation